Novel obesity drug induces up to 22% weight loss with no safety concerns
A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a significant weight reduction compared with placebo, according to top-line results from a phase 1b/2a trial.
Popular weight loss injections including Ozempic, Wegovy and Mounjaro could increase the risk of thyroid cancer within the ...
In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver ...
News Medical on MSN1h
Dapagliflozin plus calorie restriction boosts remission rates in adults with type 2 diabetes and obesityFindings indicate that dapagliflozin and calorie restriction together improve weight loss and metabolic health, increasing ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Multiple studies had already shown that their benefits might go beyond weight loss and diabetes. Those studies showed that patients taking GLP-1 medication fared better against a wide range of ...
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
A new study found that GLP-1 medications like Ozempic can lower your risk for 42 conditions, including dementia. Here's what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback